Bayer Plans More Job Cuts in Push for Fewer Bosses — Update
By Helena Smolak
Bayer plans to keep cutting jobs after it shed about 1,000 management positions in the first quarter as part of a push to run the group with fewer bosses.
Bayer's Chief Executive Bill Anderson outlined in January an internal restructuring that streamlines departments and replaces hierarchical levels with autonomous teams.
The German pharmaceutical-to-agricultural company earlier this year resisted calls for a breakup from some of its shareholders and outlined a plan that aims to bring down debt, strengthen its pharma business and address legal cases over weedkiller Roundup under its current structure.
"In the first quarter alone, we cut 1,500 jobs, around two thirds at management level," Anderson said at a press conference. The total number of jobs shed in the quarter represent about 1.5% of the group's workforce.
Bayer ended March with a staff of about 98,000, of which around 17,000 have personnel responsibility.
The company didn't specify the number of additional positions it will cut throughout the year. The company expects to achieve 500 million euros ($539.5 million) in savings this year, which will rise to EUR2 billion in 2026.
At 1241 GMT on Tuesday, shares in Bayer traded 3.1% higher at EUR30.28.
For the first quarter, the company reported a drop in net profit due to lower sales across all segments and said its results were hit by currency headwinds.
Bayer posted a first-quarter net profit of EUR2 billion, down from EUR2.18 billion the previous year but above analysts' forecasts of EUR1.73 billion, according to consensus estimates provided by Vara Research.
While the company's results show Anderson seems to be making progress on his strategy and earnings were better than expected, currency movements will likely result in a bigger hit this year than previously anticipated, analysts at Deutsche Bank said in a note.
Earnings before interest, taxes, depreciation, amortization adjusted for special items declined to EUR4.41 billion from EUR4.47 billion, Bayer said.
Sales declined 4.3% to EUR13.77 billion due to less demand across its pharmaceuticals, consumer health and crop science segments, missing a consensus forecast of EUR14.08 billion.
Net debt at the end of the quarter stood at EUR37.49 billion, up 8.7% from the three months earlier, the company said.
The company backed its currency-adjusted 2024 guidance.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
May 14, 2024 09:21 ET (13:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now